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Constitutional translocations, typically involving chromosome 3, have been recognised as a rare cause of 
inherited predisposition to renal cell carcinoma (RCC) for four decades. However, knowledge of the 
molecular basis of this association is limited. We have characterised the breakpoints by genome 
sequencing (GS) of constitutional chromosome abnormalities in five individuals who presented with RCC. 
In one individual with constitutional t(10;17)(q11.21;p11.2) the translocation breakpoint disrupted two 
genes: the known renal tumour suppressor gene (TSG) FLCN (and clinical features of Birt-Hogg-Dubé 
syndrome were detected) and RASGEF1A. In four cases the rearrangement breakpoints did not disrupt 
known inherited RCC genes. In the second case without chromosome 3 involvement the translocation 
breakpoint in an individual with a constitutional t(2;17)(q21.1;q11.2) mapped 12 Kb upstream of NLK. 
Interestingly NLK has been reported to interact indirectly with FBXW7 and a previously reported RCC-
associated translocation breakpoint disrupted FBXW7. In two cases of constitutional chromosome 3 
translocations, no candidate TSGs were identified in the vicinity of the breakpoints. However in an 
individual with a constitutional chromosome 3 inversion the 3p breakpoint disrupted the FHIT TSG (which 
has been reported previously to be disrupted in two apparently unrelated families with a RCC-associated 
t(3;8)(p14.2;q24.1). These findings a) expand the range of constitutional chromosome rearrangements 
that may be associated with predisposition to RCC, b) confirm that chromosome rearrangements not 
involving chromosome 3 can predispose to RCC, c) suggest that a variety of molecular mechanisms are 
involved the pathogenesis of translocation associated RCC and d) demonstrate the utility of genome 
sequencing for investigating such cases.  
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Introduction 
Kidney cancer accounts for almost 2% of new cancer diagnoses globally and the incidence increased by 
36% between 1990 and 2013 1. The most common form of kidney cancer in adults is renal cell carcinoma 
(RCC) which is histologically and genetically heterogeneous. Approximately 3% of cases of RCC are 
recognised as having a genetic basis and a variety of syndromic and non-syndromic forms of RCC have 
been delineated 2. Although familial forms of RCC are infrequent, the identification of the molecular basis 
of inherited RCC, as exemplified by von Hippel-Lindau (VHL; MIM 193300) disease, has been crucial to 
understanding the molecular mechanisms of sporadic cases of RCC 3. In addition to VHL, germline 
mutations in multiple other genes have been reported to predispose to RCC including BAP1, FH, FLCN, 
MET, PTEN, SDHB, SDHD, SDHA, SDHC 2,4. Furthermore constitutional translocations, particularly those 
involving chromosome 3, have been associated with inherited RCC in multiple reports.  
Four decades ago, Cohen et al. (1979) described a large kindred in which clear cell RCC segregated with 
a constitutional translocation between the short arm of chromosome 3 and the long arm of chromosome 
8, t(3;8)(p14.2;q24.1), such that the risk of RCC in translocation carriers was estimated to be 80% at age 
60 years 5. Subsequently somatic deletions of the short arm of chromosome 3 (3p) were found to be the 
most common cytogenetic abnormality in sporadic clear cell RCC suggesting the presence of critical renal 
tumour suppressor genes on 3p 6. These developments led to the suggestion that identification of 
individuals with suspected inherited forms of RCC should be screened for constitutional translocations 
involving 3p and that the characterisation of RCC-associated translocation breakpoints might lead to the 
identification of novel inherited RCC genes 7. Subsequent research studies have confirmed that the short 
arm of chromosome 3 does indeed harbour several tumour suppressor genes (TSGs) that are frequently 
inactivated in sporadic RCC (e.g. VHL, PBRM1, BAP1, RASSF1A) 8–15. 
In a review of previously published reports, we identified 17 RCC-associated constitutional translocations 
(15 of which involved a chromosome 3 breakpoint) of constitutional chromosome abnormalities 
associated with RCC (Table 1) 7,16–29. Molecular characterisation of the translocation breakpoints in 
individual cases have identified a series of candidate TSGs disrupted (or nearby) the translocation 
breakpoints (Table 4 & 5) but none of the 15 cases with chromosome 3 breakpoints were found to disrupt 
either 3p genes that are frequently mutated in sporadic RCC or known familial RCC genes that map 
outside of 3p (e.g. FLCN, FH, SDHB). The observation that the chromosome 3 breakpoints in RCC-
associated translocations were heterogeneous led to the suggestion that RCC predisposition in such 
cases might not necessarily involve disruption of a TSG but might confer susceptibility because of 
instability of the derivative chromosome 3 leading to loss at an early stage of tumourigenesis 30. 
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Assessment and characterisation of further families and individuals carrying translocations associated 
with predisposition to RCC may help elucidate the genetic features and mechanisms that lead to disease 
onset in these patients. Here, we report the results of performing genome sequencing (GS) to 
characterise five constitutional rearrangements detected in individuals with RCC and interpret the results 












Materials and Methods 
Literature review 
Reports of cases of RCC with a constitutional chromosome rearrangement were identified through a 
search of PubMed using the search terms “renal cell carcinoma” or “renal cancer” or “kidney 
cancer/tumour” and “rearrangement/inversion/translocation or chromosome” and by searching of 
previously published reports (performed January 2019). When previous reports had suggested candidate 
genes that were either close to or disrupted by the relevant chromosomal breakpoints, evidence to 
suggest that the genes were implicated in human cancer was sought by reviewing curated data from the 
Network of Cancer Genes data portal (NCG; http://ncg.kcl.ac.uk/ version 6) 31 (performed January 2019) 
where genes were classified as either ‘known cancer genes’, ‘candidate cancer genes’, or ‘non-cancer 
genes’. Genes flagged as ‘false positive cancer genes’ were designated as ‘non-cancer genes’. 
Clinical studies  
Individuals presenting with RCC and with constitutional rearrangements were ascertained through 
Regional Clinical Genetics Units in the United Kingdom. DNA was extracted from whole blood according 
to standard protocol in the referring genetics service and, when available, paraffin embedded tumour 
material was obtained from the relevant hospital histopathology department. All patients gave written 
informed consent and the study was approved by the South Birmingham Ethics Committee. 
Sequence alignment and variant calling 
DNA from four probands was sequenced at Novogene. A total of >1μg gDNA (1.2 – 1.7μg) at 
approximately 100ng/μl was used for genome sequencing (30X coverage). Generated FASTQ files were 
aligned to GRCh38 using BWA mem (version 0.7.15-r1140) 32. BAM files were sorted, PCR duplicates 
removed, and indexed, after which Indel realignment and base score recalibration was performed using 
GATK IndelRealigner and BaseRecalibrator (version 3.7-0-gcfedb67)33, respectively. Genome-wide 
variant calling was jointly performed on all samples using GATK unified genotyper (version 3.7-0-
gcfedb67) (33). DNA from one proband underwent GS as part of the NIHR BioResource Rare Diseases 
study with sequencing and primary bioinformatics performed as previously described34. Data were aligned 
to genome build GRCh37 and all analyses were performed identically with appropriate adjustments for 
differences in genome build. All genomic coordinates are reported in GRCh38 and GRCh37 coordinates 
were remapped using the NCBI remap tool (https://www.ncbi.nlm.nih.gov/genome/tools/remap). Called 
SNVs were processed and filtered for various quality control metrics and allelic frequency (supplemental 





Genome sequencing analysis: Candidate gene analysis and Breakpoint identification 
The GS results were analysed for evidence for rare, potentially pathogenic, SNVs and copy number 
abnormalities in previously reported inherited RCC genes (VHL, MET, FH, SDHB, SDHD, SDHC, BAP1, 
CDKN2B) 2,4. Copy number detection was performed using Canvas Copy Number Variant Caller (version 
1.39.0.1598)35, copy number variants were filtered to include calls only marked as “PASS”. Structural 
rearrangements and breakpoints were identified using Manta Structural Variant Caller (version 1.3.1)36. 
Manta structural variants were filtered to include only calls marked as “PASS”, number of supporting 
spanning/split reads > 5, QUAL > 100, and call frequency (Supplemental table S3). Full details of 
bioinformatic processes are described in the supplemental material. Breakpoints called on chromosomes 
matching cytogenetic reports were visually inspected using Integrative Genomics Viewer (IGV – version 
2.3.93) to confirm the presence of split and spanning reads (Supplemental figures S1-5). The data that 
support the findings of this study are available from the corresponding author upon reasonable request. 
Topologically-associated domain analysis 
TADs reported by Dixon et al. derived from human embryonic stem cells (GRCh38) were used as the 
reference TAD set 37 at 40 kb resolution. Structural variation coordinates were intersected with TAD 
coordinates using bedtools (version 2.25.0) 38. The corresponding TADs were then intersected with the 
genomic positions of all known gene loci 39(Supplemental information) to find genes contained within a 
given TAD and only protein-coding genes were included. Protein-coding genes identified within a TAD 
were assessed for potential function in cancer using the Network of Cancer Genes data portal (NCG; 
http://ncg.kcl.ac.uk/ version 6) 31, as previously described. TAD regions were visualised using the Hi-C 
data browser (http://promoter.bx.psu.edu/hi-c/index.html) 40. 
Sanger sequencing 
Direct sequencing of breakpoints was performed by Sanger sequencing using breakpoint spanning primer 
pairs (Supplemental table S2). PCR products were generated using Amplitaq Gold polymerase (Applied 
Biosystems – CA, USA) following the manufacturer’s protocol. PCR products were sequenced using the 
BigDye™ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems – CA, USA) following the 
manufacturer’s protocol. Termination sequencing products were purified by isopropanol precipitation, re-
suspended in Hi-Di Formamide (Applied Biosystems – CA, USA), and sequenced on the ABI 3730 
sequencing platform (Applied Biosystems – CA, USA). Sequences were aligned and analysed using 
Sequencher DNA analysis software (version 5.3.4; Gene Codes – MI, USA). 
Statistical tests 
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All statistical tests were performed using R project for statistical computing (version 3.5.1). Welch’s t-test 
was performed using the package BSDA (version 1.2.0) with the function tsum.test. Kruskal–Wallis rank 
sum test was performed using the base R function kruskal.test. Fisher’s exact test was performed using 
the base R function fisher.test. Statistical testing was undertaken on data from confirmed translocation 




Literature Review of Previously Reported Cases 
A total of 17 previously published distinct constitutional chromosome rearrangements were identified from 
searches of the biomedical literature (Table 1). In 15 cases (88%) chromosome 3 was involved (all of 
which were reciprocal translocations) and there were a variety of partner chromosomes in the 15 
translocation cases (e.g. three with chromosome 6, three with chromosome 8 – Table 1 and Figure 1). 
For the RCC-associated chromosome 3 translocation cases, the breakpoints were almost evenly 
distributed between the long arm (3q, n=8) and short arm (3p; n=7) and were heterogeneous (Figure 2).  
Review of the clinical and pathological data in the previously reported cases demonstrated 9 kindreds 
with at least 2 related individuals with RCC. In the 4 cases without a family history and available clinical 
information, multiple RCCs were described in 2 individuals. The mean age at diagnosis of a renal tumour 
in those cases known to carry a constitutional chromosomal rearrangement was 50 years (range 25-82 
years). Histopathological details were available for 43 cases and clear cell RCC was reported in 42 (98%) 
cases. 
Previous studies have demonstrated that cases of sporadic and familial RCC differ by mean age of 
diagnosis, with RCC presenting earlier in familial cases 41,42. Comparison of the mean age of diagnosis of 
RCC in translocation cases to familial and sporadic RCC cases (as reported previously by Maher et al.41  
& Woodward et al42) were 50.2 (SD=12.7), 48.2 (SD=12.3), and 61.8 (SD=10.8) years of age, 
respectively. Translocation cases have a statistically lower age of diagnosis than those with sporadic 
disease (Welch’s t-test, p=9.84x10-7) but no significant difference between translocation and familial 
cases was observed (Welch’s t-test, p=0.522). Though age of diagnosis across all affected 
translocation carriers is variable there was no significant difference in age between familial (with 
2 or more related individuals) translocation cases (Kruskal–Wallis test, p=0.174). 
The chromosomal rearrangement breakpoints had been mapped in 15 of 17 previously reported cases 
and a total of 10 candidate genes had been reported to be disrupted by the relevant rearrangement 
breakpoints (Table 4). Additionally, 21 genes found to be in the vicinity of translocation breakpoints and 
cited as relevant genes by the authors of the original report were also assessed (Table 5).The evidence 
for implicating the various genes in RCC predisposition was assessed using NCG data portal (Table 4 & 
5). Of the 10 genes directly disrupted by translocation breakpoints, two are classified as known cancer 
genes, with all remaining genes having no evidence supporting their role in cancer. In regards to 21 
genes stated to be in the vicinity of a translocation breakpoint, 2 were designated as known cancer genes 
and 4 were classified as candidate cancer genes. 
Clinical Features of Previously Unreported Cases 
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Five previously unreported constitutional chromosomal rearrangements ascertained through a patient 
presenting with RCC were identified through UK genetics services. The cytogenetic, clinical features and 
pathological features of the five probands and (where relevant) their affected relatives are described in 
Table 2. There were 4 translocations (involving chromosome 3 in two cases) and a pericentric inversion of 
chromosome 3 (Table 2 and Figure 1). Two or more individuals developed RCC in three kindreds. 
In the kindred with the t(3;14)(q13.3;q22) 6 individuals developed RCC (three of whom were confirmed or 
obligate translocation carriers). The proband presented with bilateral clear cell RCC at age 75 years, his 
daughter died from RCC at age 36 years, his mother and two of his brothers were reported to have 
developed RCC at ages 51, 41 and 79 years respectively. The proband’s brother was an obligate 
t(3;14)(q13.3;q22) carrier and his son developed RCC at age 67 years and was confirmed to be a 
translocation carrier.  
In the kindred with the t(3;6)(p14.2;p12) rearrangement, the proband presented with RCC at age 72 years 
and four relatives were demonstrated to also harbour the translocation. Three had not developed RCC 
(age at last follow up 47-52 years) but one (the proband’s brother) had developed bilateral clear cell RCC 
at age 55 years with unilateral recurrent disease and an adrenal metastasis at age 74 years and his son 
died from RCC at age 40 years without any record of his status for the t(3;6)(p14.2;p12) translocation.  
The index case in whom the inv(3)(p21.1q12) was identified was unaffected but was ascertained following 
a report that her cousin had developed clear cell RCC at age 39 and harboured the chromosome 3 
inversion. Other unaffected carriers of the inversion in the family included her paternal aunt and father, 
whilst her grandfather was also to be a carrier and died of carcinomatosis around age 80 years. The 
proband’s brother was diagnosed with RCC at age 48 but was not tested for the inversion. 
The t(2;17)(q21;q11.2) was identified in a 37 year old man with a poorly differentiated in part clear cell 
RCC who died from metastatic disease shortly thereafter. The translocation was maternally inherited and 
was detected in three unaffected family members (mother and two siblings) aged between 30 and 58 
years of age.  
In the kindred with the t(10;17)(q11.22;p12) the proband, with his sister, were found to have features of 
suggestive Birt-Hogg-Dubé syndrome (BHD; MIM 135150) (pneumothoraces, and fibrofolliculomas in the 
proband and multiple pulmonary cysts and fibrofolliculomas in the sister) after the diagnosis of RCC in the 
proband and the detection of the translocation. 
Molecular Characterisation of Constitutional Rearrangements in Previously Unreported Cases 
Genome sequencing did not identify any plausible likely pathogenic or pathogenic SNVs or CNVs in 
previously reported inherited RCC genes (VHL, SDHB, SDHC, SDHD, MET, FLCN, TSC1, TSC2, FH, 
PTEN, PBRM1, BAP1 and CDKN2B) in the four probands who were affected by RCC (the index case 
with the inv(3)(p21.1q12) had a family history of RCC but had not developed RCC). A novel missense 
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variant of uncertain significance by ACMG criteria 43 was identified in PBRM1 (NM_018313.4:c.2446A>T 
p.Asn816Tyr) in the t(3;6)(p14.2;p12) case. DNA from an affected individual was not available for 
sequencing in the family carrying the inv(3)(p21.1q12), as such sequencing was performed solely to 
identify candidate breakpoints. Candidate rearrangement breakpoints were identified from the GS data by 
the Manta structural variation detection algorithm in all five cases. 
Breakpoints for translocation t(3;14)(q13.3;q22) were resolved to be present at the loci chr3:125771297 
and chr14:59009871-59009875. The candidate breakpoints were supported by 7 and 9 spanning and split 
reads, respectively (Supplemental table 2). The candidate breakpoint locations identified by GS differed 
from those suggested previously by cytogenetic studies. The 3q breakpoint at chr3:125771297 is within 
cytoband 3q21 and the GS-identified 14q breakpoint at chr14:59009871 maps to 14q23 with respective 
genomic distances of 7.3 Mb and 4.7 Mb from the reported cytogenetic bands seen by karyotyping. 
Sanger sequencing confirmed the presence of the translocation breakpoints. Sanger sequencing in a 
DNA sample from his affected nephew confirmed identical breakpoints to the proband. The 3q breakpoint 
intersects with LOC105374312, an uncharacterised non-coding RNA gene and the 14q breakpoint 
disrupts the last intron of LINC01500, a long intergenic non-coding RNA gene, and is predicted to result in 
a truncated transcript lacking the final exon.  
GS in the second chromosome 3 associated translocation case t(3;6)(p14.2;p12) revealed candidate 
breakpoints at chr3:66680663 and chr6:54817716 within an AT-rich repetitive region. Breakpoint calls 
were supported by 4 and 7 spanning and split read calls, respectively (Supplemental table 2). 
Discordance between karyotyping and GS-derived cytoband positions was limited to adjacent bands with 
3p14.2 being mapped to 3p14.1 (5.5 Mb centromeric) and 6p12 being defined at a greater resolution at 
6p12.1. Sanger sequencing confirmed the presence of the translocation breakpoints. The 3p 
chromosomal breakpoint identified by GS mapped within 3p14.1 and disrupted LOC105377142, an 
uncharacterised non-coding RNA. The 6p breakpoint did not disrupt a predicted gene but was 29 kb 
upstream of FAM83B in 6p12.1. 
The candidate breakpoints in the inv(3)(p21.1q12) were identified by Manta with 11 spanning and 11 split 
reads supporting the presence of this inversion, though the number of reference spanning reads was only 
2 (Supplemental table 2). The two candidate breakpoints mapped to chr3:59964935 at 3p14.2 
(interrupting intron 7 of FHIT) and chr3:98667603 at 3q12 (47 kb upstream of ST3GAL6-AS1, a non-
coding RNA gene). The discrepancy between the cytogenetic position and GS-derived positions did not 
greatly deviate from other differences seen in other cases with the 3p breakpoint at 3p21 detected 6.6 Mb 
closer to the centromere at 3p14.2.  Though cytogenetics and Manta calls support the presence of the 
inv(3)(p14.2q12), Sanger sequencing under multiple experimental conditions failed to generate any PCR 
products and the candidate breakpoints could not be independently confirmed. 
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Assessment of the DNA at the described breakpoints for the inv(3)p14.2q12) rearrangement was 
performed to determine if local DNA features and nucleotide composition may explain the failure to 
confirm the inversion by Sanger sequencing. Analysis of each breakpoint within a ±1 Kb window 
demonstrated a lower than average GC-content percentage at both sites (chr3:59963935-59965935 = 
32.3% and chr3:98666603-98668603 = 36.6%) compared to genome-wide GC content. Furthermore, the 
3p14.2 breakpoint occurred within proximity of two repeat elements (chr3:59965304-59965360-(AT)n and 
chr3:59965818-59965936-L3) and the 3q12 breakpoint overlapped with a repetitive region 
(chr3:98667322-98667927-L1M2), as well as in proximity of five further repetitive DNA elements, as 
defined by RepeatMasker. Taken together, particularly when considering the calling of multiple 
breakpoints by Manta, low complexity and additional undetermined structural variation at either one or 
both breakpoints may explain the failure to confirm the breakpoints by Sanger sequencing. 
GS in the first of the two non-chromosome 3 translocations t(2;17)(q21;q11.2) localised the breakpoints to 
chr2:130693728 (2q21.1) and chr17:28030855 (17q11.2). The translocation breakpoint was supported by 
9 spanning and 10 split reads as called by Manta (Supplemental table 2). Sanger sequencing confirmed 
the genomic coordinates and breakpoint as a single base translocation without local rearrangement, 
insertions, or deletions. Cytogenetic positions were inconsistent for chromosome 2 (q21) with the NGS 
breakpoint occurring in the adjacent band q21.1, proximately 5.3 Mb closer to q telomere. The breakpoint 
present on chromosome 2 disrupted the coding region of two overlapping pseudogenes KLF2P3 and 
FAR2P3, as well as interrupting a CpG island spanning chr2:130693485-130693839. The nearest coding 
genes were POTEJ, AMER3, and GPR148 which were 35 kb upstream, 34 kb downstream and 62 kb 
downstream, respectively. The junction on chromosome 17 did not disrupt any known coding region but 
was 1.7 kb upstream of a reported H3K27Ac element spanning chr17:28,033,593-28,035,092, and 9.9 kb 
upstream of the NLK gene. 
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The second non-chromosome 3 translocation t(10;17)(q11.22;p12) underwent sequencing as part of the 
NIHR BioResource Rare Diseases BRIDGE project (see methods) and was analysed previously as part 
of a multiple primary tumour cohort 34 with a history of facial fibrofolliculomas, recurrent pneumothoraces 
and renal cell carcinoma. At that time no abnormality was detected but subsequently reanalysis identified 
candidate translocation breakpoints that were supported by two overlapping Manta calls for the 
chromosome 10 and chromosome 17 breakpoints at chr17:17218211-17218214 (17p11.2) and 
chr10:43236047-43236050 (10q11.21) that were supported by 22 spanning and 10 split reads and a 
secondary call at chr17:17218216-17218217 and chr10:43236058-43236059 by 15 spanning and 18 split 
reads (Supplemental table S2). As with other cases, differences between breakpoints on chromosome 10 
and 17 from both karyotyping and GS were found with 10q11.22 mapping to 10q11.21 (3.3 Mb 
centromeric) and 17p12 mapping to 17p11.2 (3.7 Mb centromeric). Given the proximity of the assigned 
breakpoint regions, a single translocation was presumed with an additional nested structural variation 
resulting in divided calling. Sanger sequencing confirmed the presence of the translocation breakpoint in 
the proband. The chromosome 17 breakpoint prediction disrupted the coding region of FLCN, falling 
within intron 9 (ENST00000285071). The chromosome 10 breakpoint disrupted the first intron of 
RASGEF1A (the first exon encodes the 5’ untranslated region proximal to the translation initiation site 
(ENST00000395810). The proband’s sibling, who was known to carry the t(10;17)(q11.22;p12), was also 
found to have evidence of BHD syndrome (multiple lung and renal cysts and facial fibrofolliculomas).  
While RNA was not available for the t(10;17)(q11.21;p11.2) proband to assess fusion gene formation, 
both genes are on the negative strand and do not appear to interrupt splice site consensus sequences, 
suggesting fusion gene products could be transcribed consisting of exon 1 of RASGEF1A with exons 10-
14 of FLCN and exons 1-9 of FLCN with exons 2-13 of RASGEF1A, from each derivative chromosome 
respectively. 
Translocations as determined by karyotyping, next generation sequencing cytobands (NGS), 
standardised nomenclature, and cytoband discrepancies are noted in Table 3. Translocations will be 
referred to by the shortened nomenclature system as described by Ordulu et al. 44 in both the text and 
tables hereafter. 
Computational evaluation of breakpoint-related genes  
The five constitutional rearrangements were confirmed or postulated to disrupt three protein coding genes 
(FHIT, FLCN and RASGEF1A). Two of these genes, FHIT and FLCN, have been previously implicated as 
renal tumour suppressor genes 45,46 and the NCG data portal classified both FHIT and FLCN as “known 
cancer genes”, RASGEF1A as a “candidate cancer gene”.  
Assessment of the effect of a translocation on the surround genomic architecture and consequently the 
impact on gene regulation is more challenging. Within the nucleus, DNA is rearranged into complex two 
dimensional and three dimensional structures, and this spatial organisation directly impacts biological 
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function. Higher order chromatin structures such as topologically associated domains (TADs) have been 
identified as pervasive and highly conserved features of genome organisation 47 and that disruption of 
these TADs and their associated genomic boundaries can lead to gene dysfunction, ectopic genomic 
interactions, and disease phenotypes 48,49. We sort to assess if any breakpoints occurred within 
topologically associated domains and to what extent, if any, these disruptions could dysregulate long 
range gene regulatory structures. 
A total of 8/10 rearrangement breakpoints occurred within a TAD (or a TAD boundary region), with the 
chromosome 3 breakpoint in t(3;14)(q21;q23) and chromosome 2 breakpoint in t(2;17)(q21.1;q11.2) 
occurring within "unorganized chromatin” regions (Table 6 and supplemental figures S7-S16). TADs 
which harboured a breakpoint were assessed for encapsulated genes and the subsequently identified 
genes assessed for relevance to cancer via the NCG (Table 6).  Analysis demonstrated two known 
cancer genes (NCOA4 and RET) and a further five candidate cancer genes (LLGL1, LRIG1, LYRM9, 
ST3GAL6, and TMEM199) were within breakpoint-containing TADs.  
Tumour Analysis 
Tumour material was available for an affected individual with the familial t(3;14)(q21;q23), and expert 
histopathological review classified the two separate tumours (A=3 cm and B=3.8 cm) for which material 
was received as clear cell RCC. Tumour A was classed as WHO/ISUP Grade 2 B (as focal grade but 
predominantly grade 2). No necrosis was seen. Immunohistochemistry on sections from Tumour B 
demonstrated staining of moderate intensity with CA-IX and AE1/3 and weak focal staining with vimentin. 
Only rare cells were CK7 positive and the tumour was negative for CD117, HMB45 and Mel-A, an 
immunoprofile consistent with the diagnosis. 
 
Using a NGS sequencing panel of 68 cancer-related genes, as described previously 50, tumour 
sequencing was performed on the two renal tumours to assess VHL mutation state. The larger tumour 
harboured a frameshift deletion in VHL (NM_000551: c.408delT: p.Phe136Leufs*23: rs397516442) in 
49% of reads but no somatic mutations in VHL were detected in the smaller tumour. Analysis of the other 
genes on the sequencing panel did not demonstrate any protein-affecting somatic alteration either tumour 
at a variant allele fraction greater than 10%. 
 
Sufficient DNA was available for one of the t(3;14)(q21;q23) tumours (tumour B, 38 mm diameter) to 
perform genome-wide copy number assessment using the Applied Biosystems OncoScan CBV FFPE 
assay kit as described previously.68  The OncoScan assay identified chromosomal alterations consistent 
with the loss of the der(3), including 3p, and retention of the wild type chromosomes (3 and 14) and 
der(14) (arr[GRCh37] 3p26.3q21.2(63410-125495356)x1,(5)x3,14q23.1q32.33(59491095-
107282024)x1,(X)x1). Additionally, the tumour also harboured trisomy 5 and loss of chromosome Y 
(Supplemental information and supplemental figures 17 & 18).  
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Discussion 
We describe five previously unreported RCC-associated constitutional chromosomal rearrangements that 
increase the total number of rearrangements reported to 22 and the number of cases in which the 
breakpoints have been characterised to 20. We found that GS enabled both the identification of candidate 
translocation breakpoints and simultaneously excluded coincidental pathogenic SNVs and CNVs in 
known hereditary cancer genes. With the increasing availability and decreasing cost of GS it will become 
increasingly feasible to characterise the molecular pathology of RCC-associated constitutional 
chromosomal rearrangements. This will improve our understanding of the relevance to individual RCC-
associated constitutional chromosomal rearrangements to the RCC tumourigenesis and we found that the 
breakpoint location reported on routine cytogenetic analysis often did not correspond to the breakpoint 
locations identified by GS. The majority (21/22, 95.5%) of RCC-associated constitutional chromosomal 
rearrangements reported to date have been associated with the clear cell variant of RCC. This is the most 
common histological subtype of sporadic RCC (75-80%) and is characterised by somatic inactivation of 
VHL and deletions of the short arm of chromosome 3 8,9,15,51. The mean age at diagnosis of RCC in the 
cases reported to date (51 years, range 25-82, n=57, SD=13.25) is younger than the average age for 
sporadic RCC (e.g. 61.8 years) 41. Whilst this is a feature of other forms of hereditary RCC (and many 
other inherited cancer types) there may also be an element of ascertainment bias with early onset cases 
more likely to be investigated for a genetic cause. In the largest family we identified, t(3;14)(q21;q23), the 
mean age at diagnosis of RCC in the 6 affected cases was 58 years and 3 individuals were either known 
or obligate translocation carriers. While the breakpoints characterised by this translocation do not disrupt 
any known cancer gene, given the loss of the derivative chromosomes is reported as the potential initiator 
of tumourigenesis in chromosome 3 translocations, the loss of der(3) would also result in the loss of 14q 
that would include the HIF1A coding region, which is a candidate 14q TSG 52. 
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In both our own and the previously published literature series, most RCC-associated constitutional 
chromosome rearrangements involved chromosome 3. Whilst this is consistent with the high frequency of 
3p allele loss in sporadic clear cell RCC, the fundamental role of somatic inactivation of the VHL TSG in 
clear cell RCC and the incidence of somatic mutations of PBRM1, BAP1 and SETD2 in RCC, to date 
most RCC-associated constitutional chromosome 3 rearrangements do not appear to disrupt known RCC 
TSGs mapping to 3p. A potential explanation for this is the observation that RCC from individuals with a 
constitutional chromosome 3 translocation can show a somatic VHL mutation on the wild-type 
chromosome 3 and loss of the derivative chromosome containing 3p (resulting in biallelic inactivation of 
the VHL TSG). This mechanism of tumourigenesis would imply that the susceptibility to RCC might result 
from instability of the translocated chromosome rather than disruption of a specific RCC TSG at the 
translocation breakpoint on chromosome 3 30 and would be consistent with the variability of the RCC-
associated chromosome 3 rearrangement breakpoints described to date (Table 1). Indeed, analysis of the 
larger of the larger of the two t(3;14)(q21;q23)-associated RCC revealed a somatic truncating VHL 
mutation and copy number alterations consistent with loss the of der(3) translocated chromosome that 
included 3p as described previously 30. Nevertheless, it is interesting that the chromosome 3 inversion we 
described was associated with a breakpoint within FHIT. Previously it was demonstrated in two 
apparently unrelated families with an RCC-associated t(3;8)(p14.2;q24.1) were reported to have 
harboured breakpoints that disrupted FHIT and RNF139 (TRC8) on 3p and 8q respectively 16,27. FHIT is 
listed as a Tier 1 known cancer gene in the Cancer Gene Census 
(https://cancer.sanger.ac.uk/cosmic/census); however, the presence of a somatic VHL mutation and loss 
of the translocated chromosome 3 in a previous t(3;8)(p14.2;q24.1)-associated RCC was unexpected 5,27. 
16 
It is possible that the recurrent involvement of FHIT in RCC-associated chromosome 3 rearrangements 
reflects the presence of palindromic AT-rich repeats at the t(3;8)(p14.2;q24.1) breakpoint and causes a 
propensity to recurrent rearrangements at this locus 53, although we note that only a fraction of 
chromosome 3 translocations are associated with predisposition to RCC 54. It is therefore conceivable 
that both instability of the translocated chromosome and monoallelic inactivation of FHIT contribute to 
RCC susceptibility. Analysis previously reported genes associated with translocations, as described by 
previous authors, and examination of TAD structures in current series identified several genes that have 
been previously reported to be located at or close to the breakpoints of RCC-associated chromosome 3 
rearrangements (Table 4-6). These genes were reviewed to determine which were included in recently 
compiled lists of known cancer genes which are based on the results of recent large scale cancer 
genomics projects; 8 genes (FHIT, LRIG1, FBXW7, CCNE1, STAG1, SEMA5B, PDZRN3, and HSPB8) 
were identified as known or candidate cancer genes from previous publications. In addition, genes that 
were disrupted (FHIT, FLCN, and RASGEF1A) or occurred within a relevant TAD structure coinciding with 
the breakpoints of the novel RCC-associated rearrangements reported here were also assessed. A total 
of ten genes that were disrupted or within breakpoint associated TAD structures were classified as known 
(FHIT, FLCN, NCOA4, and RET) or candidate cancer genes (LLGL1, LRIG1, LYRM9, RASGEF1A, 
ST3GAL6, and TMEM199) (Table 6). The independent occurrence of LRIG1 in two separate cases 
(t(3;6)(p14.1;p12.1) in this series and in Meléndez et al.27) is notable. Neither translocation directly 
disrupted the coding region of LRIG1 but have occurred within the TAD (or in close proximity in the case 
of the latter) of the gene. LRIG1 is known to encode a cell surface protein (Leucine-rich repeats and 
immunoglobulin-like domains 1; LRIG1) which is known to negatively regulate epidermal growth factor 
receptor (EGFR) 55 and ERBB-family receptor degradation including RET and MET 56,57, and deletions of 
LRIG1 occur somatically in RCC cases at a rate of 2.3% within the TCGA dataset 15, of which 94% were 
clear cell RCC. 
17 
Relatively few RCC-associated constitutional translocations not involving chromosome 3 have been 
reported. In addition to the two novel cases reported here, there are two previously reported cases 20,21 
and the translocation breakpoints were characterised in only one of these cases. It is entirely possible 
that non-chromosome 3 constitutional translocations and RCC might occur coincidentally and we note 
that, though there was an early age at onset (37 years) in the proband with t(2;17)(q21.1;q11.2) and an 
unconfirmed family history of RCC in his paternal grandfather, the translocation was also found in his 
mother and two siblings who were unaffected at ages 58, 40 and 31 years. However, identification of a 
translocation breakpoint that disrupted the FLCN gene in a patient with a t(10;17)(q11.21;p11.2) 
illustrated the value of characterising all RCC-associated constitutional rearrangements. Inactivating 
mutations in FLCN cause BHD syndrome which is characterised by facial fibrofolliculomas, pulmonary 
cysts and pneumothorax and RCC 45,58. The occurrence of fibrofolliculomas is age-dependent and 
pneumothorax occurs in a minority of cases and so BHD may present with non-syndromic RCC 59. 
However in the family reported herein the t(10;17)(q11.21;p11.2) was associated with other evidence of 
BHD syndrome. To our knowledge this is the first description of a constitutional translocation causing 
BHD syndrome.  
The other novel translocation case did not disrupt a known cancer gene but occurred close to NLK 
(Nemo-Like Kinase) a serine/threonine-protein kinase, which has been associated with the non-canonical 
Wnt and MAPK signalling pathways. Whilst NLK is currently not designated as a known cancer gene, 
evidence of tumour suppressor activity has been reported 60–62 and a role for NLK in the stabilisation of 
p53 has been suggested 63. Interestingly, NLK appears to collaborate with FBXW7 in the ubiquitination of 
c-Myb by enhancing ligation of additional ubiquitin molecules via NLK phosphorylation, leading to 
downregulation of cellular proliferation 64 and, previously, an RCC-associated constitutional translocation, 
t(3;4)(q21;q31), was demonstrated to interrupt FBXW7 18. Furthermore, FBXW7 is a designated tumour 
suppressor gene that is mutated in multiple types of primary cancers and encodes an F-box protein that is 
part of a SCF complex thought to target cyclin E and mTOR for ubiquitin-mediated degradation 65,66. Very 
recently FBXW7 has been identified as a novel cancer predisposition gene following an analysis of 
individuals with Wilms tumour 67. Additionally, it was demonstrated that FBXW7 interacts with Ubiquitin-
conjugating enzyme E2Q-like protein 1 (UBE2QL1), the gene is known to be disrupted in a previously 
reported RCC translocation case 21, suggesting an interesting connection between multiple interacting 
gene products in translocation-related RCC. 
18 
In conclusion, we report five new cases of RCC-associated constitutional chromosome rearrangements 
characterised by GS. These include the first example of a chromosome 3 inversion associated with RCC, 
the first case of a major inherited RCC gene disrupted by a translocation and a third example of a RCC 
constitutional chromosome rearrangement that disrupts FHIT. Review of the five novel cases reported 
here and previously reported cases demonstrates that RCC-associated constitutional chromosome 
rearrangements 1) mostly involve chromosome 3 but rearrangements that solely involve other 
chromosomes may also be causally linked to RCC, 2) may predispose to RCC by a variety of 
mechanisms including disruption of a tumour suppressor gene (e.g. FLCN) and/or chromosomal instability 
(as with chromosome 3 translocations), 3) can be efficiently characterised by GS and 4) can identify 
candidate pathways for RCC tumourigenesis. For chromosome 3 translocations it is unclear why most 
cases that are not ascertained because of a personal or family history of RCC appear to be associated 
with a very low risk of RCC 54. In those translocations that do predispose to RCC there may be a 
combination of factors involved including instability of the translocated chromosome during cell division 




This research was funded by the European Research Council (Advanced Researcher Award), NIHR 
(Senior Investigator Award and Cambridge NIHR Biomedical Research Centre) and Cancer Research UK 
Cambridge Cancer Centre. The views expressed are those of the authors and not necessarily those of 
the NHS or Department of Health. The University of Cambridge has received salary support in respect of 
EM from the NHS in the East of England through the Clinical Academic Reserve. ERW is supported by 
the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007). 
 
Conflict of Interest Statement 




1.  Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505. 
doi:10.1001/jamaoncol.2015.0735 
2.  Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol. 2013;23(1):10-17. 
doi:10.1016/j.semcancer.2012.06.003 
3.  Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 
2015;15(1):55-64. doi:10.1038/nrc3844 
4.  Shuch B, Zhang J. Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, 
Screening, and Management. J Clin Oncol. 2018;36(36):3560-3566. doi:10.1200/JCO.2018.79.2523 
5.  Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. 
N Engl J Med. 1979;301(11):592-595. doi:10.1056/NEJM197909133011107 
6.  Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal 
cell carcinoma. Nature. 1987;327(6124):721-724. doi:10.1038/327721a0 
7.  Boldog FL, Gemmillt RM, Wilkes CM, et al. Positional cloning of the hereditary renal carcinoma 3;8 
chromosome translocation breakpoint (suppresor gene/fagile site/polycystic kidney diease/lung 
cancer/thyroid cancer). Genetics. 1993;90:8509-8513. 
8.  Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour 
suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet. 1994;3(12):2169-2173. 
9.  Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat 
Genet. 1994;7(1):85-90. doi:10.1038/ng0594-85 
10.  Young AC, Craven RA, Cohen D, et al. Analysis of VHL Gene Alterations and their Relationship to Clinical 
Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res. 2009;15(24):7582-7592. 
doi:10.1158/1078-0432.CCR-09-2131 
11.  Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex 
gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539-542. doi:10.1038/nature09639 
12.  Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. 
Nat Genet. 2012;44(7):751-759. doi:10.1038/ng.2323 
13.  Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human 
chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(13):7504-7509. 
doi:10.1073/pnas.131216298 
14.  Morrissey C, Martinez A, Zatyka M, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor 
gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001;61(19):7277-7281. 
15.  Network CGAR, N. J, Weinstein JN, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat 
Genet. 2013;45(10):1113-1120. doi:10.1038/ng.2764 
16.  Gemmill RM, West JD, Boldog F, et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a 
patched-related gene, TRC8. Proc Natl Acad Sci U S A. 1998;95(16):9572-9577. 
17.  Bonne A, Vreede L, Kuiper RP, et al. Mapping of constitutional translocation breakpoints in renal cell cancer 
patients: identification of KCNIP4 as a candidate gene. Cancer Genet Cytogenet. 2007;179(1):11-18. 
doi:10.1016/j.cancergencyto.2007.07.005 
18.  Kuiper RP, Vreede L, Venkatachalam R, et al. The tumor suppressor gene FBXW7 is disrupted by a 
constitutional t(3;4)(q21;q31) in a patient with renal cell cancer. Cancer Genet Cytogenet. 2009;195(2):105-
111. doi:10.1016/j.cancergencyto.2009.07.001 
19.  McKay L, Frydenberg M, Lipton L, Norris F, Winship I. Case report: renal cell carcinoma segregating with a 
t(2;3)(q37.3;q13.2) chromosomal translocation in an Ashkenazi Jewish family. Fam Cancer. 2011;10(2):349-
353. doi:10.1007/s10689-010-9413-y 
20.  Doyen J, Carpentier X, Haudebourg J, et al. Renal cell carcinoma and a constitutional t(11;22)(q23;q11.2): 
case report and review of the potential link between the constitutional t(11;22) and cancer. Cancer Genet. 
2012;205(11):603-607. doi:10.1016/j.cancergen.2012.09.006 
21.  Wake NC, Ricketts CJ, Morris MR, et al. UBE2QL1 is disrupted by a constitutional translocation associated 
with renal tumor predisposition and is a novel candidate renal tumor suppressor gene. Hum Mutat. 
2013;34(12):1650-1661. doi:10.1002/humu.22433 
22.  Yusenko M V., Nagy A, Kovacs G. Molecular analysis of germline t(3;6) and t(3;12) associated with 
conventional renal cell carcinomas indicates their rate-limiting role and supports the three-hit model of 
carcinogenesis. Cancer Genet Cytogenet. 2010;201(1):15-23. 
23.  Chen J, Lui W-O, Vos MD, et al. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in 
clear cell renal cell carcinomas. Cancer Cell. 2003;4(5):405-413. doi:10.1016/S1535-6108(03)00269-1 
24.  Eleveld MJ, Bodmer D, Merkx G, et al. Molecular analysis of a familial case of renal cell cancer and a 
t(3;6)(q12;q15). Genes, Chromosom Cancer. 2001;31(1):23-32. doi:10.1002/gcc.1114 
25.  Druck T, Podolski J, Byrski T, et al. The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated 
t(2;3)(q33;q21) chromosome translocation. 2001;46(10):583-589. doi:10.1007/s100380170025 
26.  Bodmer D, Eleveld M, Kater-Baats E, et al. Disruption of a novel MFS transporter gene, DIRC2, by a familial 
21 
renal cell carcinoma-associated t(2;3)(q35;q21). Hum Mol Genet. 2002;11(6):641-649. 
27.  Meléndez B, Rodríguez-Perales S, Martínez-Delgado B, et al. Molecular study of a new family with hereditary 
renal cell carcinoma and a translocation t(3;8)(p13;q24.1). Hum Genet. 2003;112(2):178-185. 
doi:10.1007/s00439-002-0848-6 
28.  Poland KS, Azim M, Folsom M, et al. A constitutional balanced t(3;8)(p14;q24.1) translocation results in 
disruption of theTRC8 gene and predisposition to clear cell renal cell carcinoma. Genes, Chromosom Cancer. 
2007;46(9):805-812. doi:10.1002/gcc.20466 
29.  Foster RE, Abdulrahman M, Morris MR, et al. Characterization of a 3;6 translocation associated with renal 
cell carcinoma. Genes Chromosomes Cancer. 2007;46(4):311-317. doi:10.1002/gcc.20403 
30.  Bodmer D, Eleveld MJ, Ligtenberg MJL, et al. An Alternative Route for Multistep Tumorigenesis in a Novel 
Case of Hereditary Renal Cell Cancer and a t(2;3)(q35;q21) Chromosome Translocation. Am J Hum Genet. 
1998;62:1475-1483. 
31.  Repana D, Nulsen J, Dressler L, et al. The Network of Cancer Genes (NCG): a comprehensive catalogue of 
known and candidate cancer genes from cancer sequencing screens. Genome Biol. 2019;20(1):1. 
doi:10.1186/s13059-018-1612-0 
32.  Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 
2009;25(14):1754-1760. doi:10.1093/bioinformatics/btp324 
33.  McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing 
next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303. doi:10.1101/gr.107524.110 
34.  Whitworth J, Smith PS, Martin J-E, et al. Comprehensive Cancer-Predisposition Gene Testing in an Adult 
Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor 
Phenotypes. Am J Hum Genet. 2018;103(1):3-18. doi:10.1016/j.ajhg.2018.04.013 
35.  Roller E, Ivakhno S, Lee S, Royce T, Tanner S. Canvas: versatile and scalable detection of copy number 
variants. Bioinformatics. 2016;32(15):2375-2377. doi:10.1093/bioinformatics/btw163 
36.  Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for 
germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220-1222. 
doi:10.1093/bioinformatics/btv710 
37.  Dixon JR, Jung I, Selvaraj S, et al. Chromatin architecture reorganization during stem cell differentiation. 
Nature. 2015;518(7539):331-336. doi:10.1038/nature14222 
38.  Quinlan AR, Hall IM. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 
2010;26(6):841-842. doi:10.1093/bioinformatics/btq033 
39.  Smedley D, Haider S, Durinck S, et al. The BioMart community portal: an innovative alternative to large, 
centralized data repositories. Nucleic Acids Res. 2015;43(W1):W589-W598. doi:10.1093/nar/gkv350 
40.  Wang Y, Song F, Zhang B, et al. The 3D Genome Browser: A web-based browser for visualizing 3D genome 
organization and long-range chromatin interactions. Genome Biol. 2018;19(1). doi:10.1186/s13059-018-
1519-9 
41.  Maher ER, Yates JR, Ferguson-Smith M a. Statistical analysis of the two stage mutation model in von Hippel-
Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet. 
1990;27(5):311-314. doi:10.1136/jmg.27.5.311 
42.  Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER. Familial clear cell renal cell carcinoma (FCRC): 
clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet. 
2000;37(5):348-353. doi:10.1136/JMG.37.5.348 
43.  Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint 
consensus recommendation of the American College of Medical Genetics and Genomics and the Association 
for Molecular Pathology. Genet Med. 2015;17(5):405-423. doi:10.1038/gim.2015.30 
44.  Ordulu Z, Wong KE, Currall BB, et al. Describing sequencing results of structural chromosome 
rearrangements with a suggested next-generation cytogenetic nomenclature. Am J Hum Genet. 
2014;94(5):695-709. doi:10.1016/j.ajhg.2014.03.020 
45.  Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, 
and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 
2002;2(2):157-164. doi:10.1016/S1535-6108(02)00104-6 
46.  Vocke CD, Yang Y, Pavlovich CP, et al. High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-
Hogg-Dubé-Associated Renal Tumors. J Natl Cancer Inst. 2005;97(12). doi:10.1093/jnci/dji154 
47.  Dixon JR, Selvaraj S, Yue F, et al. Topological domains in mammalian genomes identified by analysis of 
chromatin interactions. Nature. 2012;485(7398):376-380. doi:10.1038/nature11082 
48.  Lupiáñez DG, Spielmann M, Mundlos S. Breaking TADs: How Alterations of Chromatin Domains Result in 
Disease. Trends Genet. 2016;32(4):225-237. doi:10.1016/j.tig.2016.01.003 
49.  Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D genome. Nat Rev Genet. 
2018;19(7):453-467. doi:10.1038/s41576-018-0007-0 
50.  Casey RT, Warren AY, Rodrigues JE, et al. Clinical and Molecular Features of Renal and 
Phaeochromocytoma/Paraganglioma Tumour Association Syndrome (RAPTAS): Case Series and Literature 
Review. J Clin Endocrinol Metab. July 2017. doi:10.1210/jc.2017-00562 
22 
51.  Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene 
alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66(4):2000-
2011. doi:10.1158/0008-5472.CAN-05-3074 
52.  Shen C, Beroukhim R, Schumacher SE, et al. Genetic and Functional Studies Implicate HIF1  as a 14q 
Kidney Cancer Suppressor Gene. Cancer Discov. 2011;1(3):222-235. doi:10.1158/2159-8290.CD-11-0098 
53.  Kato T, Franconi CP, Sheridan MB, et al. Analysis of the t(3;8) of hereditary renal cell carcinoma: a 
palindrome-mediated translocation. Cancer Genet. 2014;207(4):133-140. 
doi:10.1016/j.cancergen.2014.03.004 
54.  Woodward ER, Skytte A-B, Cruger DG, Maher ER. Population-based survey of cancer risks in chromosome 3 
translocation carriers. Genes, Chromosom Cancer. 2010;49(1):52-58. doi:10.1002/gcc.20718 
55.  Gur G, Rubin C, Katz M, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation 
and degradation. EMBO J. 2004;23(16):3270-3281. doi:10.1038/sj.emboj.7600342 
56.  Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of ret receptor tyrosine 
kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 2008;28(1):39-49. 
doi:10.1523/JNEUROSCI.2196-07.2008 
57.  Shattuck DL, Miller JK, Laederich M, et al. LRIG1 Is a Novel Negative Regulator of the Met Receptor and 
Opposes Met and Her2 Synergy. Mol Cell Biol. 2007;27(5):1934-1946. doi:10.1128/mcb.00757-06 
58.  Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet 
Oncol. 2009;10(12):1199-1206. doi:10.1016/S1470-2045(09)70188-3 
59.  Woodward ER, Ricketts C, Killick P, et al. Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: 
Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN. Clin Cancer Res. 2008;14(18):5925-
5930. doi:10.1158/1078-0432.CCR-08-0608 
60.  Emami KH, Brown LG, Pitts TEM, Sun X, Vessella RL, Corey E. Nemo-like kinase induces apoptosis and 
inhibits androgen receptor signaling in prostate cancer cells. Prostate. 2009;69(14):1481-1492. 
doi:10.1002/pros.20998 
61.  Yasuda J, Tsuchiya A, Yamada T, Sakamoto M, Sekiya T, Hirohashi S. Nemo-like kinase induces apoptosis 
in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 2003;308(2):227-233. 
62.  Han Y, Kuang Y, Xue X, et al. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in 
colorectal cancer. Biomed Pharmacother. 2014;68(5):497-505. doi:10.1016/j.biopha.2014.05.003 
63.  Zhang H-H, Li S-Z, Zhang Z-Y, et al. Nemo-like kinase is critical for p53 stabilization and function in response 
to DNA damage. Cell Death Differ. 2014;21(10):1656-1663. doi:10.1038/cdd.2014.78 
64.  Kanei-Ishii C, Nomura T, Takagi T, Watanabe N, Nakayama KI, Ishii S. Fbxw7 acts as an E3 ubiquitin ligase 
that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J Biol Chem. 2008;283(45):30540-30548. 
doi:10.1074/jbc.M804340200 
65.  Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 
Ubiquitin Ligase. Science (80- ). 2001;294(5540):173-177. doi:10.1126/science.1065203 
66.  Mao J-H, Kim I-J, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor 
suppression. Science. 2008;321(5895):1499-1502. doi:10.1126/science.1162981 
67.  Mahamdallie S, Yost S, Poyastro-Pearson E, et al. Identification of new Wilms tumour predisposition genes: 
an exome sequencing study. Lancet Child Adolesc Heal. 2019;3(5):322-331. doi:10.1016/S2352-
4642(19)30018-5 
68         Aird JJ, Nic An Riogh AU, Fleming S, Hislop RG, Sweeney P, Mayer N. Papillary Renal Cell Carcinoma With           
Osteosarcomatous Heterologous Differentiation: A Case Report With Molecular Genetic Analysis and    




Table 1: Clinical features of RCC in individuals from families with a constitutional 
chromosome rearrangement. Individuals marked * were presumed to be carriers of the 







(foci = n) 
Sex Age 
Cohen et al. 
[1979] 
t(3;8)(pl4.2;q24.1) N/a Clear cell Bilateral (n=2) M 37 
   Clear cell Bilateral (n=3) M 45 
   Clear cell Unilateral (n>2) M 59 
   Clear cell Unilateral (n=3) F 46 
   Clear cell Unilateral (n=1) M 44 
   Clear cell Unilateral (n=1) F 50 
   Clear cell Bilateral (n>3) F 41 
   Clear cell * Bilateral (n>2) M 47 
   Clear cell * Bilateral (n=9) F 44 
      Not specified Bilateral (n=7) F 39 
Kovacs et al. 
[1988] 
t(3;12)(q13.2;q24.1) N/a Clear cell Unilateral (n=1) M 50 
Kovacs et al. 
[1989] 
t(3;6)(p13;q25.1) N/a Clear cell Bilateral (n = 5) M 53 
Koolen et al. 
[1998] 
t(2;3)(q35;q21) N/a Clear cell Bilateral (n=3) M 54 
   Not specified N/a F 53 
   Clear cell Unilateral (n=3) F 68 
   Clear cell Unilateral (n=1) M 40 
      Clear cell Bilateral (n=2) M 30 
Van Kessel et al. 
[1999] 
t(3;4)(p13;p16) N/a Clear cell N/a M 52 
Eleveld et al. 
[2001] 
t(3;6)(q11.2;q13) N/a Clear cell Unilateral F 59 
   Clear cell Unilateral F 41 
   Clear cell Unilateral F 63 
      Clear cell Unilateral M 67 
Kanayama et al. t(1;3)(q32;q13.3) N/a Clear cell Unilateral (n=1) F 79 
24 
[2001] 
   Clear cell Bilateral (n=4) M 56 
   Clear cell * Unilateral (n=1) M 70 
      Clear cell Unilateral (n=1) M 62 
Podolski et al. 
[2001] 
t(2;3)(q33;q21) N/a Clear cell N/a M 45 
   Clear cell N/a M 38 
   Clear cell * N/a M 51 
   Clear cell * N/a F 51 
   Clear cell * N/a F 51 
   Clear cell * Bilateral M 51 
      Clear cell * N/a F 63 
Meléndez et al. 
[2003] 
t(3;8)(p14.1;q24.23) N/a Clear cell Bilateral (n=2) M 46 
   Clear cell Bilateral (n=N/a) F 56 
   Clear cell * N/a M 68 
   Clear cell Bilateral (n=N/a) M 25 
   Clear cell Bilateral (n=N/a) M 66 
   Clear cell Bilateral (n=N/a) M 82 
   Clear cell Bilateral (n=N/a) M 44 
   Clear cell Bilateral (n=N/a) F 39 




Bonne et al. 
[2007] 
t(3;15)(p11;q21) N/a Clear cell N/a F 49 
  ins(3;13)(p24.2;q32q21.2)   Clear cell N/a N/a 74 





Bilateral (n=3) M 49 
Poland et al. 
[2007] 
t(3;8)(p14;q24.1)  Clear cell Bilateral (n=N/a) F 47 
      Clear cell Bilateral (n=N/a) M 39 





Clear cell N/a N/a 45 
McKay et al. 
[2010] 
t(2;3)(q37.3;q13.2) N/a Clear cell Bilateral (n=8) M 54 
25 
   Clear cell N/a M 50 
      Clear cell Unilateral (n > 1) F 35 
Doyen et al. 
[2012] 
t(11;22)(q23-24;q11.2-12) N/a Clear cell Unilateral (n=1) M 72 







Unilateral (n=2) F 35 




Bilateral (n>2) F 36 
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t(2;17)(q21.1;q11.2) Proband Yes M 37 Clear cell N/a Yes 
chr2:130693727 
chr17:28031855 













Sibling 1 Yes ? 40 Unaffected N/a 
 
N/a N/a 
  Sibling 2 Yes ? 31 Unaffected N/a   N/a N/a 












and an adrenal 
metastasis, 
age 74 years 
 
Relative 2 Yes ? N/a Not specified 
 
   
 
Relative 3 Yes ? N/a Unaffected 
 
  
Last follow up 
47-52 years 
 
Relative 4 Yes ? N/a Unaffected 
 
  
Last follow up 
47-52 years 
  Relative 5 Yes ? N/a Unaffected       
Last follow up 
47-52 years 











Yes F N/a Unaffected 
 
   
 
Father Yes M N/a Unaffected 
 
   
 




aged 80 years 
  Brother N/a M 48 Not specified N/a       












Brother Obligate M 79 Not specified N/a No N/a  
 
Daughter Unknown F 36 Not specified N/a No N/a  
 
Brother Unknown M 41 Not specified N/a No N/a  
  Mother Unknown F 50 Not specified N/a No N/a  
















Table 3: Details of cytogenetic karyotype, NGS-derived cytogenetic positions, and 
standardised nomenclature for chromosomal alterations described in this series. 
 

























Table 4. Reassessment of genes disrupted by translocation breakpoints in RCC-
associated translocations reported previously. Genes were categorised according to 
their current status in NCG v6.0 (Repana et al. 2019) 
Original 
publication 
Affected genes Position (GRCh38) Known cancer gene (NCG 6.0) 
Cohen et al. 
[1979] 
FHIT chr3:59747587-61251459 Known cancer gene 
Cohen et al. 
[1979] 
RNF139 (TRC8) chr8:124474738-124488618 Non-cancer gene 
Kovacs et al. 
[1989] 
STXBP5 chr6:147204358-147390476 Non-cancer gene 
Koolen et al. 
[1998] 
SLC49A4 (DIRC2) chr3:122794795-122881139 Non-cancer gene 
van Kessel et al. 
[1999] 
KCNIP4 chr4:20728606-21948801 Non-cancer gene 
Kanayama et al. 
[2001] 
LSAMP chr3:115802363-117139389 Non-cancer gene 
Kanayama et al. 
[2001] 
RASSF5 (NORE1) chr1:206507530-206589448 Non-cancer gene 
Podolski et al. 
[2001] 
DIRC1 chr2:188733738-188839420 Non-cancer gene 
Kuiper et al. 
[2009] 
FBXW7 chr4:152320544-152536095 Known cancer gene 
Wake et al. 
[2013] 





Table 5: Reassessment of genes highlighted as being close to translocation breakpoints 
in RCC-associated translocations reported previously. Genes were categorised 
according to their current status in NCG v6.0 (Repana et al. 2019) 
Original 
publication 
Affected genes Position (GRCh38) Known cancer gene (NCG 6.0) 
Meléndez et al. 
[2003] 
LRIG1 chr3:66378797-66501263 Candidate cancer gene 
Wake et al. 
[2013] 
CCNE1 chr19:29811898-29824312 Known cancer gene 
Kuiper et al. 
[2009] 
C3orf56 chr3:127193131-127198185 Non-cancer gene 
Foster et al. 
[2007] 
PPP2R3A chr3:135965673-136147891 Non-cancer gene 
Foster et al. 
[2007] 
PCCB chr3:136250306-136337896 Non-cancer gene 
Foster et al. 
[2007] 
STAG1 chr3:136336233-136752403 Known cancer gene 
Foster et al. 
[2007] 
MSL2 (RNF184) chr3:136148922-136197241 Non-cancer gene 
Foster et al. 
[2007] 
EPHB1 chr3:134597801-135260467 Non-cancer gene 
Foster et al. 
[2007] 
EPHA7 chr6:93240020-93419547 Non-cancer gene 
Podolski et al. 
[2001] 
HIBCH chr2:190189735-190344193 Non-cancer gene 
Podolski et al. 
[2001] 
INPP1 chr2:190343470-190371665 Non-cancer gene 
Podolski et al. 
[2001] 
HNRNPC (HNRPC) chr14:21209136-21269494 Non-cancer gene 
Koolen et al. 
[1998] 
HSPBAP1 chr3:122740003-122793824 Non-cancer gene 
Koolen et al. 
[1998] 
SEMA5B chr3:122909082-123028605 Candidate cancer gene 
Yusenko et al. 
[2010] 
PDZRN3 chr3:73382433-73624940 Candidate cancer gene 
Yusenko et al. 
[2010] 
CNTN3 chr3:74262568-74521140 Non-cancer gene 
31 
Yusenko et al. 
[2010] 
NECTIN3 (PVRL3) chr3:111070071-111275563 Non-cancer gene 
Yusenko et al. 
[2010] 
HSPB8 chr12:119178642-119221131 Candidate cancer gene 
Yusenko et al. 
[2010] 
CCDC60 chr12:119334712-119541047 Non-cancer gene 
Cohen et al. 
[1979] 
TRMT12 chr8:124450820-124462150 Non-cancer gene 
Cohen et al. 
[1979] 


















Table 6. Assessment of genes disrupted by (*) or within the same topologically 
associating domain as RCC-associated rearrangement reported in the current series. 
Genes were categorised according to their current status in NCG v6.0 (Repana et al. 
2019) 






Chr. Start End 
TAD 
chr. 
TAD start TAD end 
Cancer 
genes 
inv(3)(p21.1q12) chr3 59964935 59964935 chr3 59920000 61400000 FHIT *1 
 chr3 98667603 98667603 chr3 98600000 99800000 ST3GAL6 2 
t(10;17)(q11.22;p12) chr17 17218211 17218214 chr17 16840000 18400000 
FLCN *1 
LLGL1 2 




t(2;17)(q21.1;q11.2) chr2 130693728 130693728 NA N/A N/A N/A 
 chr17 28030855 28030855 chr17 27640000 28360000 
LYRM9 2 
TMEM199 2 
t(3;14)(q13.3;q22) chr3 125771297 125771297 NA N/A N/A N/A 
 chr14 59009871 59009871 chr14 58440000 59080000 N/A 
t(3;6)(p14.2;p12) chr6 54817716 54817716 chr6 53720000 55240000 N/A 
 chr3 66680663 66680663 chr3 66240000 66880000 LRIG1 2 
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Figure legends 
Figure 1  
Circos plots visualising constitutional chromosomal rearrangements. Previously published translocations 
shown in blue and rearrangements identified in this study shown in orange. Width of the region at the 
ends of each ribbon represents the proportion of each chromosome which is translocated with its 
corresponding translocation partner. 1A contains all previously published translocations and 
translocations in the current series. 1B contains only previously published translocations. 1C contains 
only rearrangements in this series. 
Figure 2 
Diagram illustrating the position of chromosome 3 translocation breakpoints across the p and q arms. 
Differentially shaded portions represent different cytobands, the red region represents the centromeric 
region. Positions given in cases without base pair resolution are the median position for a given cytoband 
in the translocation karyotype. 
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